Motexafin Gadolinium
Category: CancerMotexafin Gadolinium Overview
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.[1] History On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2] On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3 ...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Motexafin_gadolinium
Recent Motexafin Gadolinium Forums:
Be the first to start a discussion about this drug.Other drugs which contain Motexafin Gadolinium or a similar ingredient: (1 result)
- XCYTRIN Motexafin Gadolinium